First-of-its-Kind Health Economic Analysis Shows Early Use of Fast Diagnostics in Sepsis Care Could Save Thousands of Lives and Reduce Health System Costs Across G7 Countries
Fast diagnostics could prevent 36,200 deaths and 84,400 sepsis cases annually in
The analysis is the first to provide evidence that early use of fast diagnostics can reduce preventable deterioration into sepsis, improve patient outcomes, and generate substantial cost savings for healthcare systems consistently across all studied countries. Conducted by the
"Every year, over 884,000 Americans are hospitalized with bloodstream infections. Our analysis shows that early diagnostics could prevent 84,400 from deteriorating into sepsis and save 36,200 lives. These findings support the priorities laid out in US sepsis and antimicrobial stewardship policies, and they demand action. At bioMérieux, we are committed to ensuring that every patient receives the right diagnostic at the right time and hope this will further encourage governments, payers, and health systems to advance structural reforms needed to expand timely access to fast ID/AST," explains
Unmet Needs in Sepsis Management
Sepsis, a life-threatening reaction to an infection, is responsible for 21 million deaths globally each year.i In
As a result, nearly 1 in 5 bloodstream infection patients receive an inappropriate initial treatment increasing the risk of deterioration and driving higher costs for the hospital and health system.iv
The model-based health economic analysis evaluates what would happen if fast ID/AST were systematically used early in the care pathway before clinical deterioration occurs. Built using real‑world hospital data from
Faster Identification Significantly Improves Patient Outcomes
Previous studies have demonstrated that fast ID/AST technologies can return actionable diagnostic results within less than 30 hours, substantially shortening time‑to‑results compared to the standard of care in each country. The OHE analysis builds on this established evidence by quantifying the clinical impact of deploying these faster diagnostics early in the care pathway.
Across all seven countries, the results from the model-based health economic evaluation show that early access to diagnostic information can prevent thousands of patients with bloodstream infection from progressing to sepsis or septic shock annually. Notably, the number of reported sepsis cases fell by an average of more than 20%. This leads to fewer sepsis related deaths and a significant reduction in long-term post sepsis complications, improving patient's quality of life.
A System-Wide Return on Investment
Across all G7 countries, the evaluation shows that deploying fast ID/AST early in the care pathway is consistently cost saving, regardless of how each health system is structured or financed.
Importantly, 53% to 83% of all savings occur during the initial hospitalization, when the clinical and economic consequences of deterioration are most concentrated[v] because early diagnostic information prevents the likelihood that patients progress into one of the most resource intensive stages of sepsis care.
Fast ID/AST deliver an estimated
The Case for Policy Change
Today, diagnostics represent only a small fraction of healthcare spending, yet remain constrained by value frameworks that fail to capture their broader health system and population-level impact, bundled reimbursement models that treat them as costs rather than value generating tools, and misaligned incentives where laboratories bear the expense while savings are realized by other parts of the health system.
"Our health economic analysis demonstrates that these diagnostics deliver substantial value for both patients and health systems, far exceeding their upfront cost. This provides US policymakers with a clear, evidence-based rationale to rethink how diagnostics are valued and funded," says Dr.
This call for policy change is already gaining traction in current US policy priorities: the US National Action Plan for Combating Antibiotic-Resistant Bacteria calls for advancing the development and use of rapid and innovative diagnostic testsvi while
The full article, The Value of
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 46 countries and serves more than 160 countries with the support of a large network of distributors. In 2025, revenues reached €4.1 billion, with over 94% of sales outside of
bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
www.biomerieux.com.
|
|
bioMérieux is listed on the Symbol: BIM – ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg: BIM.FP |
i Gray A, Chung E, Hsu R et al. Global, regional, and national sepsis incidence and mortality, 1990–2021: a systematic analysis.
ii Centers for Disease Control and Prevention (
iii Bauer, K.A., Perez, K.K., Forrest, G.N. and Goff, D.A., 2014. Review of rapid diagnostic tests used by antimicrobial stewardship programs. Clinical Infectious Diseases: An Official Publication of the
iv Kadri, S.S., Lai, Y.L., Warner, S., Strich, J.R., Babiker, A., Ricotta, E.E., Demirkale, C.Y., Dekker, J.P., Palmore, T.N., Rhee, C., Klompas, M., Hooper, D.C., Powers, J.H., Srinivasan, A., Danner, R.L. and Adjemian, J., 2021a. Inappropriate Empiric Antibiotic Therapy in Bloodstream Infections at
v Hassan S., Hamlyn T., Fong H., Hampson G. 2026. The Value of
vi U.S. Department of
View original content to download multimedia:https://www.prnewswire.com/news-releases/first-of-its-kind-health-economic-analysis-shows-early-use-of-fast-diagnostics-in-sepsis-care-could-save-thousands-of-lives-and-reduce-health-system-costs-across-g7-countries-302747246.html
SOURCE bioMérieux
